search
Back to results

Stem Cell Transplant for Hemoglobinopathy

Primary Purpose

Sickle Cell Disease, Thalassemia, Severe Congenital Neutropenia

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Busulfan, Fludarabine, ATG, TLI
Busulfan, Cyclophosphamide, ATG, GCSF
Campath, Fludarabine, Cyclophosphamide
Total Body Irradiation
Stem cell infusion
Sponsored by
Masonic Cancer Center, University of Minnesota
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Sickle Cell Disease focused on measuring high risk hemoglobinopathy, stem cell transplant, donor lymphocyte infusion, transfusion dependent, stem cell donor, cord blood, marrow, transfusion dependent non-malignant hematologic disorders

Eligibility Criteria

undefined - 50 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Patients with Sickle Cell Disease/Thalassemia (SCD/THAL) 0-50 years of age with an acceptable stem cell donor and disease characteristic defined by the following: Stroke, central nervous system (CNS) hemorrhage or a neurologic event lasting longer than 24 hours, or abnormal cerebral magnetic resonance imaging (MRI) or cerebral arteriogram or MRI angiographic study and impaired neuropsychological testing Acute chest syndrome with a history of recurrent hospitalizations or exchange transfusions Recurrent vaso-occlusive pain 3 or more episodes per year for 3 years or more years or recurrent priapism, Impaired neuropsychological function and abnormal cerebral MRI scan Stage I or II sickle lung disease, Sickle nephropathy (moderate or severe proteinuria or a glomerular filtration rate [GFR] 30-50% of the predicted normal value) Bilateral proliferative retinopathy and major visual impairment in at least one eye Osteonecrosis of multiple joints with documented destructive changes Requirement for chronic transfusions but with red blood cell (RBC) alloimmunization >2 antibodies during long term transfusion therapy Patients with transfusion dependent alpha- or beta-thalassemia 0-35 years of age with an acceptable stem cell donor as defined in the criteria in section above. Patients with other non-malignant hematologic disorders that are transfusion-dependent or involve other potentially life-threatening cytopenias (including but not limited to Severe Congenital Neutropenia, Diamond-Blackfan Anemia and Shwachman-Diamond Syndrome) who are 0-35 years of age with an acceptable stem cell donor Second Transplants Patients with sickle cell disease or thalassemia who have failed to engraft or have autologous recovery after a myeloablative SCT regimen or non-myeloablative regimen are eligible for this protocol. Regimen A2 will be utilized for patients with sickle cell disease or thalassemia who do not have an HLA-identical sibling donor or for any patient who has pre-existing organ dysfunction making them ineligible for a myeloablative preparative regimen. Regimen B will be utilized for patients with sickle cell disease or thalassemia who have an HLA-identical sibling donor. Patients must meet above criteria. If the patient has received prior radiation therapy, eligibility to receive additional radiation therapy must be determined by Dr. Dusenbery If first transplant was a non-myeloablative regimen, the second transplant can occur at any time If the first transplant was a myeloablative regimen, then the second transplant must be > 6 months from the first transplant Exclusion Criteria: Patients with one or more of the following: Karnofsky or Lansky performance score <70 Acute hepatitis or evidence of moderate or severe portal fibrosis or cirrhosis on biopsy Stage III-IV lung disease GFR<30% predicted Pregnant or lactating females Active serious infection whereby patient has been on intravenous antibiotics for one week prior to study entry. Any patient with AIDS or ARC or HIV seropositivity Psychologically incapable of undergoing bone marrow transplant (BMT) with associated strict isolation or documented history of medical non-compliance Patients not able to receive total lymphocytic irradiation (TLI) due to prior radiation therapy

Sites / Locations

  • Masonic Cancer Center, University of Minnesota

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Other

Experimental

Experimental

Arm Label

RIC Bu/Flu (A) (discontinued)

MA Bu/Cy (B)

RIC Cy/Flu/TBI (A2)

Arm Description

Full Preparative Regimen for subjects with matched donors using Busulfan on Day -8 and -7, Fludarabine on Day -6 through -2, antithymocyte globulin (ATG) on Day -2 through -1, total lymphoid radiation (TLI) on Day -1, stem cell infusion on Day 0.

Myeloablative Preparative Regimen for subjects with HLA identical sibling donors consists of Busulfan on day -9 through -6, Cyclophosphamide on day -5 through -2, ATG on day -3 through -1, stem cell infusion on Day 0 and Granulocyte Colony Stimulating Factor on day -3 until ANC >2500 x 2 days.

Patients with sickle cell disease or thalassemia who do not have an HLA-identical sibling donor or who has pre-existing organ dysfunction making myeloablative condition ineligible will receive Campath on day -10 through -6, Cyclophosphamide on day -7, Fludarabine on day -6 through -2, total body irradiation (TBI) on day -1, stem cell infusion on Day 0.

Outcomes

Primary Outcome Measures

Number of Patients Who Experienced Grade 3-5 Treatment Related Toxicity
In general, grade 3 equates to moderate, grade 4 to severe and grade 5 to death.

Secondary Outcome Measures

The Incidence of Chimerism at 100 Days
The number of patients whose blood and/or bone marrow contains > 10% donor cells.
The Incidence of Chimerism at 6 Months
The number of patients whose blood and/or bone marrow contains > 10% donor cells.
The Incidence of Chimerism at 1 Year
The number of patients whose blood and/or bone marrow contains > 10% donor cells.
The Incidence of Grade 2-4 Acute Graft Versus Host Disease (Acute GVHD)
The number of patients who experienced grades 2-4 Acute GVHD. Acute GVHD is when the donated bone marrow or peripheral blood stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body. Grades 2-4 equate to mild to severe disease. Symptoms typically appear within weeks after transplant.
The Incidence of Grade 3-4 Acute Graft Versus Host Disease (Acute GVHD)
The number of patients who experienced grades 3-4 Acute GVHD. Acute GVHD is when the donated bone marrow or peripheral blood stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body. IGrades 3-4 equate to moderate to severe disease. Symptoms typically appear within weeks after transplant.
The Incidence of Chronic Graft Versus Host Disease (Chronic GVHD)
The number of patients who experienced Chronic GVHD. Chronic GVHD is when the donated bone marrow or peripheral blood stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body. Chronic GVHD can appear at any time after allogeneic transplant or several years after transplant.
The Incidence of Chronic Graft Versus Host Disease (Chronic GVHD)
The number of patients who experienced Chronic GVHD. Chronic GVHD is when the donated bone marrow or peripheral blood stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body. Chronic GVHD can appear at any time after allogeneic transplant or several years after transplant.
Change in the Patient's Quality of Life as Compared to the Pre-Transplant Assessment
The measure for quality of life used in this study is the Karnofsky Performance Score. The Karnofsky Performance Score runs from 100 to 0, where 100 is "perfect" health and 0 is death.
Change in the Patient's Quality of Life as Compared to the Pre-Transplant Assessment
The measure for quality of life used in this study is the Karnofsky Performance Score. The Karnofsky Performance Score runs from 100 to 0, where 100 is "perfect" health and 0 is death.
Change in the Patient's Quality of Life as Compared to the Pre-Transplant Assessment
The measure for quality of life used in this study is the Karnofsky Performance Score. The Karnofsky Performance Score runs from 100 to 0, where 100 is "perfect" health and 0 is death.
Determine Physical Characteristics and Biologic Effects of Mixed Populations of Donor and Host Red Blood Cells
Determine the Concentration of Campath in the Serum
Overall Survival
Number of patients alive 100 days after transplant.
Overall Survival
Number of patients alive 1 year after transplant.
Disease Free Survival
Number of patients alive without disease 100 days after transplant.
Disease Free Survival
Number of patients alive without disease 1 year after transplant.

Full Information

First Posted
September 12, 2005
Last Updated
February 13, 2020
Sponsor
Masonic Cancer Center, University of Minnesota
Collaborators
National Marrow Donor Program
search

1. Study Identification

Unique Protocol Identification Number
NCT00176852
Brief Title
Stem Cell Transplant for Hemoglobinopathy
Official Title
Allogeneic Hematopoietic Stem Cell Transplant for Patients With High Risk Hemoglobinopathy Using a Preparative Regimen to Achieve Stable Mixed Chimerism
Study Type
Interventional

2. Study Status

Record Verification Date
February 2020
Overall Recruitment Status
Completed
Study Start Date
June 2002 (undefined)
Primary Completion Date
March 2014 (Actual)
Study Completion Date
January 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Masonic Cancer Center, University of Minnesota
Collaborators
National Marrow Donor Program

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study tests the clinical outcomes of one of two preparative regimens (determined by available donor source) in patients with non-malignant hemoglobinopathies. The researchers hypothesize that these regimens will have a positive effect on post transplant engraftment and the incidence of graft-versus-host-disease. Regimen A2 has replaced Regimen A in this study. Two patients were treated on Regimen A but did not have evidence of initial engraftment thus triggering the stopping rule for that arm of this study.
Detailed Description
Prior to transplantation, subjects will receive either: Cyclophosphamide, Fludarabine, Campath, Total body irradiation (TBI) Or Busulfan, Cyclophosphamide, antithymocyte globulin (ATG), granulocyte colony-stimulating factor (GSCF) These drugs (and the radiation) are being given to help the new stem cells take and grow. On the day of transplantation, subjects will receive stem cells transfused via intravenous (IV) catheter. After stem cell transplantation, subjects will be given cyclosporine-A and mycophenolate (MMF)/or Methylprednisone/or Methotrexate to reduce the risk of graft-versus-host disease, the complication that occurs when the donor's stem cells react against the patient.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sickle Cell Disease, Thalassemia, Severe Congenital Neutropenia, Diamond-Blackfan Anemia, Shwachman-Diamond Syndrome
Keywords
high risk hemoglobinopathy, stem cell transplant, donor lymphocyte infusion, transfusion dependent, stem cell donor, cord blood, marrow, transfusion dependent non-malignant hematologic disorders

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
22 (Actual)

8. Arms, Groups, and Interventions

Arm Title
RIC Bu/Flu (A) (discontinued)
Arm Type
Other
Arm Description
Full Preparative Regimen for subjects with matched donors using Busulfan on Day -8 and -7, Fludarabine on Day -6 through -2, antithymocyte globulin (ATG) on Day -2 through -1, total lymphoid radiation (TLI) on Day -1, stem cell infusion on Day 0.
Arm Title
MA Bu/Cy (B)
Arm Type
Experimental
Arm Description
Myeloablative Preparative Regimen for subjects with HLA identical sibling donors consists of Busulfan on day -9 through -6, Cyclophosphamide on day -5 through -2, ATG on day -3 through -1, stem cell infusion on Day 0 and Granulocyte Colony Stimulating Factor on day -3 until ANC >2500 x 2 days.
Arm Title
RIC Cy/Flu/TBI (A2)
Arm Type
Experimental
Arm Description
Patients with sickle cell disease or thalassemia who do not have an HLA-identical sibling donor or who has pre-existing organ dysfunction making myeloablative condition ineligible will receive Campath on day -10 through -6, Cyclophosphamide on day -7, Fludarabine on day -6 through -2, total body irradiation (TBI) on day -1, stem cell infusion on Day 0.
Intervention Type
Drug
Intervention Name(s)
Busulfan, Fludarabine, ATG, TLI
Other Intervention Name(s)
Busulfex, Fludara, ATG, Total lymphoid Irradiation
Intervention Description
Busulfan 0.8 mg/kg/dose intravenous (IV) Days -8 and -7 Fludarabine 35 mg/m2 IV Days -6 through -2 Antithymocyte globulin (ATG) 30 mg/kg IV Days -2 and -1 Total lymphoid radiation 300 cGy
Intervention Type
Drug
Intervention Name(s)
Busulfan, Cyclophosphamide, ATG, GCSF
Other Intervention Name(s)
Busulfex, Cytoxan, antithymocyte globulin, granulocyte colony-stimulating factor
Intervention Description
Busulfan 0.8 mg/kg/dose intravenous (IV) Days -9 through -6 Cyclophosphamide 50 mg/kg IV Days -5 through -2 ATG 30 mg/kg IV Day -1 GCSF 5 mcg/kg/day IV until ANC >2500 x 2 days.
Intervention Type
Drug
Intervention Name(s)
Campath, Fludarabine, Cyclophosphamide
Other Intervention Name(s)
Fludara, alemtuzumab, Cytoxan
Intervention Description
Receives Campath-1H 0.2 mg/kg Days -10 through -6, Fludarabine 35 mg/m2 intravenous (IV) Days -6 through -2, total body irradiation (TBI) 300 cGy Day -1.
Intervention Type
Radiation
Intervention Name(s)
Total Body Irradiation
Other Intervention Name(s)
TBI
Intervention Description
300 cGY Day -1
Intervention Type
Procedure
Intervention Name(s)
Stem cell infusion
Other Intervention Name(s)
bone marrow transplant
Intervention Description
Given Day 0
Primary Outcome Measure Information:
Title
Number of Patients Who Experienced Grade 3-5 Treatment Related Toxicity
Description
In general, grade 3 equates to moderate, grade 4 to severe and grade 5 to death.
Time Frame
1 year
Secondary Outcome Measure Information:
Title
The Incidence of Chimerism at 100 Days
Description
The number of patients whose blood and/or bone marrow contains > 10% donor cells.
Time Frame
100 days
Title
The Incidence of Chimerism at 6 Months
Description
The number of patients whose blood and/or bone marrow contains > 10% donor cells.
Time Frame
6 months
Title
The Incidence of Chimerism at 1 Year
Description
The number of patients whose blood and/or bone marrow contains > 10% donor cells.
Time Frame
1 year
Title
The Incidence of Grade 2-4 Acute Graft Versus Host Disease (Acute GVHD)
Description
The number of patients who experienced grades 2-4 Acute GVHD. Acute GVHD is when the donated bone marrow or peripheral blood stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body. Grades 2-4 equate to mild to severe disease. Symptoms typically appear within weeks after transplant.
Time Frame
100 days
Title
The Incidence of Grade 3-4 Acute Graft Versus Host Disease (Acute GVHD)
Description
The number of patients who experienced grades 3-4 Acute GVHD. Acute GVHD is when the donated bone marrow or peripheral blood stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body. IGrades 3-4 equate to moderate to severe disease. Symptoms typically appear within weeks after transplant.
Time Frame
100 days
Title
The Incidence of Chronic Graft Versus Host Disease (Chronic GVHD)
Description
The number of patients who experienced Chronic GVHD. Chronic GVHD is when the donated bone marrow or peripheral blood stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body. Chronic GVHD can appear at any time after allogeneic transplant or several years after transplant.
Time Frame
6 months
Title
The Incidence of Chronic Graft Versus Host Disease (Chronic GVHD)
Description
The number of patients who experienced Chronic GVHD. Chronic GVHD is when the donated bone marrow or peripheral blood stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body. Chronic GVHD can appear at any time after allogeneic transplant or several years after transplant.
Time Frame
1 year
Title
Change in the Patient's Quality of Life as Compared to the Pre-Transplant Assessment
Description
The measure for quality of life used in this study is the Karnofsky Performance Score. The Karnofsky Performance Score runs from 100 to 0, where 100 is "perfect" health and 0 is death.
Time Frame
pre-transplant
Title
Change in the Patient's Quality of Life as Compared to the Pre-Transplant Assessment
Description
The measure for quality of life used in this study is the Karnofsky Performance Score. The Karnofsky Performance Score runs from 100 to 0, where 100 is "perfect" health and 0 is death.
Time Frame
1 year
Title
Change in the Patient's Quality of Life as Compared to the Pre-Transplant Assessment
Description
The measure for quality of life used in this study is the Karnofsky Performance Score. The Karnofsky Performance Score runs from 100 to 0, where 100 is "perfect" health and 0 is death.
Time Frame
2 years
Title
Determine Physical Characteristics and Biologic Effects of Mixed Populations of Donor and Host Red Blood Cells
Time Frame
During study
Title
Determine the Concentration of Campath in the Serum
Time Frame
Day 0
Title
Overall Survival
Description
Number of patients alive 100 days after transplant.
Time Frame
100 days
Title
Overall Survival
Description
Number of patients alive 1 year after transplant.
Time Frame
1 year
Title
Disease Free Survival
Description
Number of patients alive without disease 100 days after transplant.
Time Frame
100 days
Title
Disease Free Survival
Description
Number of patients alive without disease 1 year after transplant.
Time Frame
1 year

10. Eligibility

Sex
All
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with Sickle Cell Disease/Thalassemia (SCD/THAL) 0-50 years of age with an acceptable stem cell donor and disease characteristic defined by the following: Stroke, central nervous system (CNS) hemorrhage or a neurologic event lasting longer than 24 hours, or abnormal cerebral magnetic resonance imaging (MRI) or cerebral arteriogram or MRI angiographic study and impaired neuropsychological testing Acute chest syndrome with a history of recurrent hospitalizations or exchange transfusions Recurrent vaso-occlusive pain 3 or more episodes per year for 3 years or more years or recurrent priapism, Impaired neuropsychological function and abnormal cerebral MRI scan Stage I or II sickle lung disease, Sickle nephropathy (moderate or severe proteinuria or a glomerular filtration rate [GFR] 30-50% of the predicted normal value) Bilateral proliferative retinopathy and major visual impairment in at least one eye Osteonecrosis of multiple joints with documented destructive changes Requirement for chronic transfusions but with red blood cell (RBC) alloimmunization >2 antibodies during long term transfusion therapy Patients with transfusion dependent alpha- or beta-thalassemia 0-35 years of age with an acceptable stem cell donor as defined in the criteria in section above. Patients with other non-malignant hematologic disorders that are transfusion-dependent or involve other potentially life-threatening cytopenias (including but not limited to Severe Congenital Neutropenia, Diamond-Blackfan Anemia and Shwachman-Diamond Syndrome) who are 0-35 years of age with an acceptable stem cell donor Second Transplants Patients with sickle cell disease or thalassemia who have failed to engraft or have autologous recovery after a myeloablative SCT regimen or non-myeloablative regimen are eligible for this protocol. Regimen A2 will be utilized for patients with sickle cell disease or thalassemia who do not have an HLA-identical sibling donor or for any patient who has pre-existing organ dysfunction making them ineligible for a myeloablative preparative regimen. Regimen B will be utilized for patients with sickle cell disease or thalassemia who have an HLA-identical sibling donor. Patients must meet above criteria. If the patient has received prior radiation therapy, eligibility to receive additional radiation therapy must be determined by Dr. Dusenbery If first transplant was a non-myeloablative regimen, the second transplant can occur at any time If the first transplant was a myeloablative regimen, then the second transplant must be > 6 months from the first transplant Exclusion Criteria: Patients with one or more of the following: Karnofsky or Lansky performance score <70 Acute hepatitis or evidence of moderate or severe portal fibrosis or cirrhosis on biopsy Stage III-IV lung disease GFR<30% predicted Pregnant or lactating females Active serious infection whereby patient has been on intravenous antibiotics for one week prior to study entry. Any patient with AIDS or ARC or HIV seropositivity Psychologically incapable of undergoing bone marrow transplant (BMT) with associated strict isolation or documented history of medical non-compliance Patients not able to receive total lymphocytic irradiation (TLI) due to prior radiation therapy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Angela Smith, MD
Organizational Affiliation
Masonic Cancer Center, University of Minnesota
Official's Role
Principal Investigator
Facility Information:
Facility Name
Masonic Cancer Center, University of Minnesota
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55455
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Stem Cell Transplant for Hemoglobinopathy

We'll reach out to this number within 24 hrs